News | Computed Tomography (CT) | May 18, 2021

CT features help select patients with stage IA non-small cell lung cancer for sublobar resection, rather than more extensive surgery

(A) 70-year-old woman with pulmonary adenocarcinoma who underwent sublobar resection without evidence for pLVI. 15-mm solid nodule with irregular margins present in right lower lobe (arrow). No tumor recurrence on 37-month follow-up. (B) 75-year-old man with pulmonary adenocarcinoma who underwent wedge resection that exhibited pLVI. 19-mm solid nodule with irregular margins and peritumoral interstitial thickening (arrowheads) present in right upper lobe. Ipsilateral mediastinal and hilar lymph node metastas

(A) 70-year-old woman with pulmonary adenocarcinoma who underwent sublobar resection without evidence for pLVI. 15-mm solid nodule with irregular margins present in right lower lobe (arrow). No tumor recurrence on 37-month follow-up. (B) 75-year-old man with pulmonary adenocarcinoma who underwent wedge resection that exhibited pLVI. 19-mm solid nodule with irregular margins and peritumoral interstitial thickening (arrowheads) present in right upper lobe. Ipsilateral mediastinal and hilar lymph node metastasis occurred after 5-month follow-up (not shown). Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


May 18, 2021 — According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR), computed tomography (CT) features may help identify which patients with stage IA non-small cell lung cancer are optimal candidates for sublobar resection, rather than more extensive surgery.

This retrospective study included 904 patients (453 men, 451 women; mean age, 62 years) who underwent lobectomy (n=574) or sublobar resection (n=330) for stage IA non-small cell lung cancer. Two thoracic radiologists independently evaluated findings on preoperative chest CT, later resolving any discrepancies. Recurrences were identified via medical record review.

"In patients with stage IA non-small cell lung cancer, pathologic lymphovascular invasion was observed only in solid-dominant part solid nodules and solid nodules with solid portion diameter over 10 mm," concluded corresponding author Mi Young Kim from the department of radiology at the University of Ulsan College of Medicine, Asan Medical Center.

"Among such nodules," the authors of this AJR article continued, "peritumoral interstitial thickening (odds ratio=13.22) and pleural contact (odds ratio=2.45) were independently associated with pathologic lymphovascular invasion." Moreover, models incorporating these features independently predicted recurrence-free survival after sublobar resection (hazard ratio=5.37-6.05).

For more information: www.arrs.org

Related Content

Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time August 12, 2022
arrow
News | ASTRO

August 12, 2022 — The American Society for Radiation Oncology (ASTRO) today expressed its support for President Joseph R ...

Time August 12, 2022
arrow
News | Radiology Education

August 11, 2022 — After a three-year break, this spring featured the return of the anticipated Canon Roadshow Events ...

Time August 11, 2022
arrow
News | Computed Tomography (CT)

August 11, 2022 — For the first time, researchers successfully captured CT images of an entire woolly mammoth tusk ...

Time August 11, 2022
arrow
News | Radiology Imaging

August 11, 2022 — Bracco Imaging S.p.A. has announced the renewal of the “Bracco Fellowships” initiative, in partnership ...

Time August 11, 2022
arrow
News | Ultrasound Imaging

August 10, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ...

Time August 10, 2022
arrow
News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Point-of-Care Ultrasound (POCUS)

August 10, 2022 — Mindray North America, a global leader and developer of healthcare technologies and solutions for ...

Time August 10, 2022
arrow
News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
Subscribe Now